Integrum Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Scott Flora

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

Slammed 38% Integrum AB (publ) (STO:INTEG B) Screens Well Here But There Might Be A Catch

Aug 30

CEO

Scott Flora (68 yo)

less than a year

Tenure

Mr. Scott D. Flora is the Acting CEO since September 15, 2024 and serves as Director from September 27, 2023 and he previously served as Adjunct Board Member of Integrum AB (publ) since May 11, 2023 until...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Rickard Branemark	Founder	2.5yrs	SEK 3.40m	geen gegevens
Scott Flora	Acting CEO & Director	less than a year	geen gegevens	geen gegevens
Jorgen Svanstrom	Interim Chief Finance Officer	1.5yrs	geen gegevens	geen gegevens
Inger Rydin	Chief Operating Officer	less than a year	geen gegevens	geen gegevens
Karin Ganlöv	Chief Medical Officer	2.5yrs	geen gegevens	geen gegevens
Jeffrey Zanni	President of U.S. & Head of American Operations	1.3yrs	geen gegevens	geen gegevens
Jerry Frimanson	Head of Supply	less than a year	geen gegevens	geen gegevens
Anna-Tove Branemark	Chief Executive Officer of Integrum Inc.	no data	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van INTEG B wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Rickard Branemark	Founder	no data	SEK 3.40m	geen gegevens
Scott Flora	Acting CEO & Director	1.2yrs	geen gegevens	geen gegevens
Bengt Sjoholm	Chairman	5yrs	SEK 100.00k	geen gegevens
Karin Wingstrand	Director	no data	SEK 100.00k	geen gegevens
Andrew Christensen	Director	no data	SEK 100.00k	geen gegevens
Patric Lindgren	Independent Director	4.8yrs	SEK 376.29k	geen gegevens
Cecilia Wikstrom	Independent Director	4.8yrs	SEK 100.00k	geen gegevens

4.8yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van INTEG B wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Integrum Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Less than half of directors are independent

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum AB (Publ) Announces Management Changes

Recent updates

Inger Rydin Announces Executive Changes

Integrum Announces Change in Chief Executive Officer

First quarter 2025 earnings released

Consensus revenue estimates fall by 18%

Price target decreased by 19% to kr62.50

Slammed 38% Integrum AB (publ) (STO:INTEG B) Screens Well Here But There Might Be A Catch

New major risk - Share price stability

Integrum AB (publ), Annual General Meeting, Sep 25, 2024

Consensus EPS estimates fall by 37%, revenue upgraded

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

Consensus revenue estimates decrease by 12%

Price target decreased by 31% to kr72.00

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Consensus revenue estimates decrease by 40%

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Consensus forecasts updated

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

First quarter 2023 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q2, 2023 Results on Dec 05, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Price target decreased to kr100.00

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Owner & Chairman exercised options to buy kr1.4m worth of stock.

Investor sentiment improved over the past week

Integrum's (STO:INTEG B) Earnings Aren't As Good As They Appear